FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896800413> ?p ?o ?g. }

• W2896800413 endingPage "120" @default.
• W2896800413 startingPage "115" @default.
• W2896800413 abstract "Genomic analyses in oncologic care allow for the development of more precise clinical laboratory tests that will be critical for personalized pharmacotherapy. Traditional biopsy-based approaches are limited by the availability of sequential tissue specimens to detect resistance. Blood-based genomic profiling (“liquid biopsy”) is useful for longitudinal monitoring of tumor genomes and can complement biopsies. Tumor-associated mutations can be identified in cell-free tumor DNA (ctDNA) from patient blood samples and used for monitoring disease activity. The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non–small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non–small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma. Chromosomal aberration pattern analysis by low-coverage whole genome sequencing is a new, broader approach. Genomic imbalances detected in cell-free DNA (cfDNA) can be used to compute a copy number instability (CNI) score. In clinical studies, it was demonstrated that the change in CNI score can serve as an early predictor of therapeutic response to chemotherapy/immunotherapy of many cancer types. In multivariable models, it could be shown that the CNI score was superior to clinical parameters for prediction of overall survival in patients with head and neck cancer. There is emerging evidence for the clinical validity of ctDNA testing regarding identification of candidates for targeted therapies, prediction of therapeutic response, early detection of recurrence, resistance mutation detection, measuring genetic heterogeneity, tumor burden monitoring, and risk stratification. Improvement of sensitivity to detect tumors at very early stages is difficult due to insufficient mutant DNA fraction of ≤0.01%. Further developments will include validation in prospective multicenter interventional outcome studies and the development of digital platforms to integrate diagnostic data." @default.
• W2896800413 created "2018-10-26" @default.
• W2896800413 creator A5052246537 @default.
• W2896800413 creator A5055085283 @default.
• W2896800413 creator A5069783216 @default.
• W2896800413 creator A5071754471 @default.
• W2896800413 date "2019-04-01" @default.
• W2896800413 modified "2023-10-13" @default.
• W2896800413 title "Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer Therapy" @default.
• W2896800413 cites W1546552389 @default.
• W2896800413 cites W1975348342 @default.
• W2896800413 cites W1980497534 @default.
• W2896800413 cites W1984169395 @default.
• W2896800413 cites W2015438948 @default.
• W2896800413 cites W2023068069 @default.
• W2896800413 cites W2075191363 @default.
• W2896800413 cites W2102316672 @default.
• W2896800413 cites W2104190624 @default.
• W2896800413 cites W2113754052 @default.
• W2896800413 cites W2121110176 @default.
• W2896800413 cites W2140575188 @default.
• W2896800413 cites W2150757282 @default.
• W2896800413 cites W2160463964 @default.
• W2896800413 cites W2161566942 @default.
• W2896800413 cites W2179502834 @default.
• W2896800413 cites W2206697844 @default.
• W2896800413 cites W2221447926 @default.
• W2896800413 cites W2269582226 @default.
• W2896800413 cites W2277335334 @default.
• W2896800413 cites W2323306940 @default.
• W2896800413 cites W2345952503 @default.
• W2896800413 cites W2486521428 @default.
• W2896800413 cites W2494541315 @default.
• W2896800413 cites W2566478217 @default.
• W2896800413 cites W2570341714 @default.
• W2896800413 cites W2582875120 @default.
• W2896800413 cites W2598988196 @default.
• W2896800413 cites W2605731475 @default.
• W2896800413 cites W2611088102 @default.
• W2896800413 cites W2611907031 @default.
• W2896800413 cites W2615393916 @default.
• W2896800413 cites W2621272124 @default.
• W2896800413 cites W2623769367 @default.
• W2896800413 cites W2765435739 @default.
• W2896800413 cites W2768081668 @default.
• W2896800413 cites W2774583854 @default.
• W2896800413 cites W2790122515 @default.
• W2896800413 cites W2801341790 @default.
• W2896800413 cites W4234746319 @default.
• W2896800413 cites W775417740 @default.
• W2896800413 doi "https://doi.org/10.1097/ftd.0000000000000566" @default.
• W2896800413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30883505" @default.
• W2896800413 hasPublicationYear "2019" @default.
• W2896800413 type Work @default.
• W2896800413 sameAs 2896800413 @default.
• W2896800413 citedByCount "29" @default.
• W2896800413 countsByYear W28968004132019 @default.
• W2896800413 countsByYear W28968004132020 @default.
• W2896800413 countsByYear W28968004132021 @default.
• W2896800413 countsByYear W28968004132022 @default.
• W2896800413 countsByYear W28968004132023 @default.
• W2896800413 crossrefType "journal-article" @default.
• W2896800413 hasAuthorship W2896800413A5052246537 @default.
• W2896800413 hasAuthorship W2896800413A5055085283 @default.
• W2896800413 hasAuthorship W2896800413A5069783216 @default.
• W2896800413 hasAuthorship W2896800413A5071754471 @default.
• W2896800413 hasConcept C121608353 @default.
• W2896800413 hasConcept C126322002 @default.
• W2896800413 hasConcept C143998085 @default.
• W2896800413 hasConcept C152110520 @default.
• W2896800413 hasConcept C172680121 @default.
• W2896800413 hasConcept C2775934546 @default.
• W2896800413 hasConcept C2776256026 @default.
• W2896800413 hasConcept C2777306565 @default.
• W2896800413 hasConcept C2777658100 @default.
• W2896800413 hasConcept C2778258057 @default.
• W2896800413 hasConcept C2779234561 @default.
• W2896800413 hasConcept C2779529041 @default.
• W2896800413 hasConcept C2780416959 @default.
• W2896800413 hasConcept C2781187634 @default.
• W2896800413 hasConcept C2781230642 @default.
• W2896800413 hasConcept C32220436 @default.
• W2896800413 hasConcept C502942594 @default.
• W2896800413 hasConcept C526805850 @default.
• W2896800413 hasConcept C54355233 @default.
• W2896800413 hasConcept C60644358 @default.
• W2896800413 hasConcept C71924100 @default.
• W2896800413 hasConcept C86803240 @default.
• W2896800413 hasConceptScore W2896800413C121608353 @default.
• W2896800413 hasConceptScore W2896800413C126322002 @default.
• W2896800413 hasConceptScore W2896800413C143998085 @default.
• W2896800413 hasConceptScore W2896800413C152110520 @default.
• W2896800413 hasConceptScore W2896800413C172680121 @default.
• W2896800413 hasConceptScore W2896800413C2775934546 @default.
• W2896800413 hasConceptScore W2896800413C2776256026 @default.
• W2896800413 hasConceptScore W2896800413C2777306565 @default.
• W2896800413 hasConceptScore W2896800413C2777658100 @default.
• W2896800413 hasConceptScore W2896800413C2778258057 @default.

• next